Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the acceptability and safety of switching to
Suboxone® (buprenorphine plus naloxone) and the effect of the switch on medication
dispensing. Subjects, for whom a therapy with Suboxone® is indicated and planned prior to
study enrollment and who are willing to participate, will initiate therapy on Day 1 of the
study. The dosage will be adjusted between Day 2 to 7 depending on patient's needs and
determined by the treating physicians in accordance with the SmPC of Suboxone®. Data will be
collected at baseline, day 1 til 7, the end of weeks 2 and 4 and monthly up to the end of
Month 12.
Details
Lead Sponsor:
Indivior Inc.
Treatments:
Analgesics, Opioid Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone